PURPOSE: Tamoxifen is a major treatment modality for estrogen receptor positive breast cancer, but the occurrence of resistance remains a problem. Recently, obesity-related leptin has been found to interfere with tamoxifen in breast cancer MCF-7 cells. In the present study we investigated the effect of leptin on three tamoxifen-treated breast cancer cell types (i.e., MDA-MB-231, MCF-7 and MCF-7/HER2). METHODS: The effect of tamoxifen/leptin treatment was evaluated using a MTT cell viability assay. mRNA expression was assessed by real time PCR and protein expression by Western blotting. WWOX, Survivin and BCL2 gene promoter activities were evaluated by chromatin immunoprecipitation. RESULTS: Cell viability assays revealed that estrogen receptor negative MDA-MB-231 cells were resistant, that estrogen receptor positive MCF-7 cells were sensitive and that MCF-7/HER2 cells were relatively resistant to tamoxifen, while leptin co-administration 'rescued' MCF-7 and, especially, MCF-7/HER2 cells from the anti-proliferative effect of tamoxifen. The cell lines also exhibited a different phosphorylation status of STAT3, a transcription factor that is activated by the obesity related leptin receptor b (Ob-Rb). Most importantly, chromatin immunoprecipitation assays revealed differential STAT3 binding to the anti-apoptotic BCL2 and pro-apoptotic WWOX gene promoters in MCF-7 and MCF-7/HER2 cells, leading to concomitant modifications of its mRNA/protein expression levels, thus providing a selective advantage to HER2 over-expressing MCF-7/HER2 cells after treatment with tamoxifen and tamoxifen plus leptin. CONCLUSIONS: Our study provides novel evidence indicating that synergy between the leptin/Ob-Rb/STAT3 signalling pathway and the HER2 receptor protects tamoxifen-treated HER2 over-expressing cells from the inhibitory effect of tamoxifen through differential regulation of apoptosis-related genes.
PURPOSE:Tamoxifen is a major treatment modality for estrogen receptor positive breast cancer, but the occurrence of resistance remains a problem. Recently, obesity-related leptin has been found to interfere with tamoxifen in breast cancer MCF-7 cells. In the present study we investigated the effect of leptin on three tamoxifen-treated breast cancer cell types (i.e., MDA-MB-231, MCF-7 and MCF-7/HER2). METHODS: The effect of tamoxifen/leptin treatment was evaluated using a MTT cell viability assay. mRNA expression was assessed by real time PCR and protein expression by Western blotting. WWOX, Survivin and BCL2 gene promoter activities were evaluated by chromatin immunoprecipitation. RESULTS: Cell viability assays revealed that estrogen receptor negative MDA-MB-231 cells were resistant, that estrogen receptor positive MCF-7 cells were sensitive and that MCF-7/HER2 cells were relatively resistant to tamoxifen, while leptin co-administration 'rescued' MCF-7 and, especially, MCF-7/HER2 cells from the anti-proliferative effect of tamoxifen. The cell lines also exhibited a different phosphorylation status of STAT3, a transcription factor that is activated by the obesity related leptin receptor b (Ob-Rb). Most importantly, chromatin immunoprecipitation assays revealed differential STAT3 binding to the anti-apoptotic BCL2 and pro-apoptotic WWOX gene promoters in MCF-7 and MCF-7/HER2 cells, leading to concomitant modifications of its mRNA/protein expression levels, thus providing a selective advantage to HER2 over-expressing MCF-7/HER2 cells after treatment with tamoxifen and tamoxifen plus leptin. CONCLUSIONS: Our study provides novel evidence indicating that synergy between the leptin/Ob-Rb/STAT3 signalling pathway and the HER2 receptor protects tamoxifen-treated HER2 over-expressing cells from the inhibitory effect of tamoxifen through differential regulation of apoptosis-related genes.
Authors: R Devos; Y Guisez; J Van der Heyden; D W White; M Kalai; M Fountoulakis; G Plaetinck Journal: J Biol Chem Date: 1997-07-18 Impact factor: 5.157
Authors: Qian Gao; Michael J Wolfgang; Susanne Neschen; Katsutaro Morino; Tamas L Horvath; Gerald I Shulman; Xin-Yuan Fu Journal: Proc Natl Acad Sci U S A Date: 2004-03-22 Impact factor: 11.205
Authors: Bharat B Aggarwal; Gautam Sethi; Kwang Seok Ahn; Santosh K Sandur; Manoj K Pandey; Ajaikumar B Kunnumakkara; Bokyung Sung; Haruyo Ichikawa Journal: Ann N Y Acad Sci Date: 2006-12 Impact factor: 5.691
Authors: Elena Fiorio; Anna Mercanti; Marianna Terrasi; Rocco Micciolo; Andrea Remo; Alessandra Auriemma; Annamaria Molino; Veronica Parolin; Bruno Di Stefano; Franco Bonetti; Antonio Giordano; Gian Luigi Cetto; Eva Surmacz Journal: BMC Cancer Date: 2008-10-22 Impact factor: 4.430
Authors: K Vazquez-Santillan; J Melendez-Zajgla; L Jimenez-Hernandez; G Martínez-Ruiz; V Maldonado Journal: Cell Oncol (Dordr) Date: 2015-08-29 Impact factor: 6.730
Authors: Monserrat Olea-Flores; Juan Carlos Juárez-Cruz; Miguel A Mendoza-Catalán; Teresita Padilla-Benavides; Napoleón Navarro-Tito Journal: Int J Mol Sci Date: 2018-11-06 Impact factor: 5.923
Authors: Andreas Heinzel; Maximilian Marhold; Paul Mayer; Michael Schwarz; Erwin Tomasich; Arno Lukas; Michael Krainer; Paul Perco Journal: PLoS One Date: 2019-01-25 Impact factor: 3.240
Authors: Paweł Madej; Grzegorz Franik; Piotr Kurpas; Aleksander Owczarek; Jerzy Chudek; Magdalena Olszanecka-Glinianowicz Journal: Dis Markers Date: 2016-05-12 Impact factor: 3.434